TY - JOUR
T1 - Gut microbiota and IBD
T2 - Causation or correlation?
AU - Ni, Josephine
AU - Wu, Gary D.
AU - Albenberg, Lindsey
AU - Tomov, Vesselin T.
N1 - Funding Information:
J.N. acknowledges support from the National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007066-40) and holds the AGA-Takeda Pharmaceuticals Research Scholar Award in Inflammatory Bowel Disease. G.D.W. acknowledges funding from PennCHOP Microbiome Program, NIH grants R01 DK107565, R24 AI 118629, and the Crohn’s and Colitis Foundation Microbiome Initiative. L.A. acknowledges support from grant K23DK109136-01. V.T.T. acknowledges support from NIH grant K08-DK097301.
Publisher Copyright:
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - A general consensus exists that IBD is associated with compositional and metabolic changes in the intestinal microbiota (dysbiosis). However, a direct causal relationship between dysbiosis and IBD has not been definitively established in humans. Findings from animal models have revealed diverse and context-specific roles of the gut microbiota in health and disease, ranging from protective to pro-inflammatory actions. Moreover, evidence from these experimental models suggest that although gut bacteria often drive immune activation, chronic inflammation in turn shapes the gut microbiota and contributes to dysbiosis. The purpose of this Review is to summarize current associations between IBD and dysbiosis, describe the role of the gut microbiota in the context of specific animal models of colitis, and discuss the potential role of microbiota-focused interventions in the treatment of human IBD. Ultimately, more studies will be needed to define host-microbial relationships relevant to human disease and amenable to therapeutic interventions.
AB - A general consensus exists that IBD is associated with compositional and metabolic changes in the intestinal microbiota (dysbiosis). However, a direct causal relationship between dysbiosis and IBD has not been definitively established in humans. Findings from animal models have revealed diverse and context-specific roles of the gut microbiota in health and disease, ranging from protective to pro-inflammatory actions. Moreover, evidence from these experimental models suggest that although gut bacteria often drive immune activation, chronic inflammation in turn shapes the gut microbiota and contributes to dysbiosis. The purpose of this Review is to summarize current associations between IBD and dysbiosis, describe the role of the gut microbiota in the context of specific animal models of colitis, and discuss the potential role of microbiota-focused interventions in the treatment of human IBD. Ultimately, more studies will be needed to define host-microbial relationships relevant to human disease and amenable to therapeutic interventions.
UR - http://www.scopus.com/inward/record.url?scp=85029670713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029670713&partnerID=8YFLogxK
U2 - 10.1038/nrgastro.2017.88
DO - 10.1038/nrgastro.2017.88
M3 - Review article
C2 - 28743984
AN - SCOPUS:85029670713
SN - 1759-5045
VL - 14
SP - 573
EP - 584
JO - Nature Reviews Gastroenterology and Hepatology
JF - Nature Reviews Gastroenterology and Hepatology
IS - 10
ER -